Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

49.85 -0.55 (-1.09%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
36 37 Next >
News headline image
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
Via Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference ↗
Cramer shared his insights during his attendance at JPMorgan's healthcare conference, 
Via Benzinga
Topics Artificial Intelligence
News headline image
2 Growth Stocks That Could Make You Richer in 2024 and Beyond ↗
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
News headline image
Why Is LumiraDx (LMDX) Stock Down 13% Today? ↗
LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday! 
Via InvestorPlace
News headline image
3 Great Foreign Companies to Invest in Right Now ↗
These international companies can bring a helpful new flavor to your investment portfolio. 
Via The Motley Fool
News headline image
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)... 
Via Talk Markets
Stocks Commence 2024 Bullish Rally: LMDX, HNRC, BULT, HALB, SPZI
Via AB Newswire
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M ↗
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. 
Via Benzinga
News headline image
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry ↗
Which weight-loss stocks are good buys today? 
Via The Motley Fool
News headline image
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
News headline image
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know ↗
It isn't the first drugmaker to partner with the chipmaker, and it won't be the last. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
From Genentech
Via Business Wire
News headline image
Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO ↗
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering. 
Via Benzinga
Topics Regulatory Compliance
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in December ↗
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
News headline image
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
From Roivant Sciences
Via GlobeNewswire
News headline image
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
News headline image
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen... 
Via Benzinga
News headline image
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
From Genentech
Via Business Wire
News headline image
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
From Genentech
Via Business Wire
News headline image
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
News headline image
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
From Genentech
Via Business Wire
News headline image
Why Viking Therapeutics Was Crushing It This Week ↗
Nowadays, it's good to be a developer of next-generation weight loss drugs. 
Via The Motley Fool
News headline image
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities ↗
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
News headline image
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer ↗
Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in... 
Via Benzinga
News headline image
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti 
Via Benzinga
News headline image
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
News headline image
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative ↗
 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.